Combining the low doses with Noom's GLP-1 Companion support app "helps more patients stay on the treatment, experience the full health benefits of these medications, and make real progress in reducing obesity and overweight rates in the US," said the company's chief medical officer, Dr Jeffrey Egler
In addition, the long-term effects and side effects of GLP-1R agonists need more in-depth studies
Clinical evidence in T2DM management A wide range of clinical trials and research have been performed to assess the effectiveness, safety, and tolerability of short-acting against long-acting GLP-1 analogues in the treatment and management of T2DM and obesity
It is a clinical necessity for anyone pursuing long-term metabolic health
What should you ask your healthcare provider before starting Tirzepatide
That competition works in your favor